Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial

Abstract This phase Ib study compared the effects of AZD9977, a selective mineralocorticoid receptor modulator with predicted low hyperkalemia risk, with spironolactone on serum potassium (sK+) in patients with heart failure (HF) with preserved or mildly reduced ejection fraction (EF; ≥40%), and ren...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Iain B. Squire, Anders Gabrielsen, Peter J. Greasley, Linda Wernevik, Judith Hartleib‐Geschwindner, Julie Holden, Susanne Johansson, Anna Rudvik, José Sánchez, Krister Bamberg, Johanna Melin, Andrew Whittaker
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2022-10-01
Serie:	Clinical and Translational Science
Accesso online:	https://doi.org/10.1111/cts.13377
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!